The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GERN | -15.48% | -21.11% | -4.63% | -79% |
| S&P | +16.91% | +77.79% | +12.19% | +967% |
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $48.02M | 1.0% |
| Gross Profit | $46.71M | -0.1% |
| Gross Margin | 97.28% | -1.1% |
| Market Cap | $842.63M | -60.6% |
| Market Cap / Employee | $3.27M | 0.0% |
| Employees | 258 | 12.7% |
| Net Income | -$31,144.00K | -22.8% |
| EBITDA | -$10,515.00K | 46.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $79.44M | -1.8% |
| Accounts Receivable | $36.99M | 2.9% |
| Inventory | 116.6 | 201.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $233.13M | 3.5% |
| Short Term Debt | $18.45M | -13.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.72% | 20.6% |
| Return On Invested Capital | -63.88% | 3.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$22,067.00K | 49.6% |
| Operating Free Cash Flow | -$22,067.00K | 49.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.44 | 3.35 | 3.37 | 3.39 | -53.62% |
| Price to Sales | 9.10 | 5.71 | 4.98 | 4.79 | -84.32% |
| Price to Tangible Book Value | 3.44 | 3.35 | 3.37 | 3.39 | -53.62% |
| Enterprise Value to EBITDA | -55.36 | -65.81 | -57.66 | -73.46 | -33.79% |
| Return on Equity | -45.3% | -31.1% | -29.6% | -33.9% | -48.72% |
| Total Debt | $247.69M | $249.81M | $251.25M | $251.57M | 2.05% |
GERN earnings call for the period ending December 31, 2024.
GERN earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
